In:
Liver International, Wiley, Vol. 35, No. 1 ( 2015-01), p. 71-78
Abstract:
Renal toxicity of first generation protease inhibitors ( PI s) was not a safety signal in phase III clinical trials, but was recently reported in recent studies. It appeared important to determine the clinical significance of these findings. Methods We retrospectively analysed 101 HCV patients receiving triple therapy with telaprevir ( n = 36) or boceprevir ( n = 26) or double therapy ( n = 39) with peginterferon and ribavirin and having a close monitoring of eGFR (MDRD formula) during and after treatment. EGFR decline over time was assessed by a linear mixed‐effects model (LMEM) with search for possible explanatory covariates. Results Patients treated with telaprevir presented a significant decrease of eGFR with the same kinetics: initial decrease at W (week) 4, nadir at W8 (mean decrease 17.0 ± 18.9 ml/min/1.73 m 2 ) and return to baseline at W16. The W8 eGFR was correlated with the D0 eGFR ( R 2 = 0.49). The LMEM showed that interindividual variability in the slope of eGFR vs time between D0 and W8 was non‐significant and eGFR nadir could be predicted from eGFR obtained at D0. In multivariate analysis, eGFR intercept (i.e. baseline value) was associated with older age and male sex. Conclusion The eGFR significantly varied in telaprevir group only. Our model showed that eGFR nadir mainly depended on initial eGFR . As telaprevir has been shown to inhibit mostly the drug transporter OCT2 which interacts with creatinine transport, the early decrease of eGFR observed could be a benign phenomenon. However, as unpredictable true renal toxicity may occur during therapy, we recommend a thorough follow‐up of eGFR .
Type of Medium:
Online Resource
ISSN:
1478-3223
,
1478-3231
DOI:
10.1111/liv.2015.35.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2124684-1
